Brilinta tablet/adult indications and dosage: Difference between revisions
| Line 11: | Line 11: | ||
BRILINTA is a [[P2Y12]] platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with [[acute coronary syndrome]] (ACS) ([[unstable angina]], non-ST elevation myocardial infarction, or ST elevation [[myocardial infarction]]). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to [[clopidogrel]]. The difference between treatments was driven by CV death and [[MI]] with no difference in [[stroke]]. In patients treated with [[PCI]], it also reduces the rate of stent [[thrombosis]] [[Brilinta tablet/clinical studies|Clinical Studies]]. | BRILINTA is a [[P2Y12]] platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with [[acute coronary syndrome]] (ACS) ([[unstable angina]], non-ST elevation myocardial infarction, or ST elevation [[myocardial infarction]]). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to [[clopidogrel]]. The difference between treatments was driven by CV death and [[MI]] with no difference in [[stroke]]. In patients treated with [[PCI]], it also reduces the rate of stent [[thrombosis]] [[Brilinta tablet/clinical studies|Clinical Studies]]. | ||
BRILINTA has been studied in [[ACS]] in combination with [[aspirin]]. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of [[aspirin]] above 100 mg daily See [[Brilinta tablet/warnings|warnings]] and [[Brilinta tablet/clinical studies|Clinical Studies]]. | BRILINTA has been studied in [[ACS]] in combination with [[aspirin]]. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of [[aspirin]] above 100 mg daily See [[Brilinta tablet/warnings|warnings]] and [[Brilinta tablet/clinical studies|Clinical Studies]].<ref>{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = 21 March 2014 }}</ref> | ||
===Off-Label Use and Dosage (Adult)=== | ===Off-Label Use and Dosage (Adult)=== | ||
Latest revision as of 15:36, 21 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
FDA-Labeled Indications and Dosage (Adult)
Acute Coronary Syndromes
BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis Clinical Studies.
BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily See warnings and Clinical Studies.[1]
Off-Label Use and Dosage (Adult)
{{{offLabelAdult}}}
References
- ↑ "BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP]". Retrieved 21 March 2014.